Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 525-526

  Agheli, Aref ^a   Sal, Chang Park ^a   Huang, Chien Jen ^b   Wang, Jen C ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b St John's Queens Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; NANOPARTICLE; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; LETTER; LIVER METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA, CLEAR CELL; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 67249125033     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328329979f     Document Type: Letter

References (13)

1. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Onc 2000; 18:1062-1067. (Pubitemid 30123784)
2. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Onc 2007; 25:2902-2908. (Pubitemid 47123154)
3. Huinink WB, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-2193. (Pubitemid 27251118)
4. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96:902-905. (Pubitemid 40255525)
5. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV III. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006; 100:437-438. (Pubitemid 43075284)
6. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099-2106.
7. Trimble EL. Innovative therapies for the advanced ovarian cancer. Semin Oncol 2000; 27 (Suppl 7):24-30. (Pubitemid 30643849)
8. McGuire WP. Paclitaxel in the treatment of ovarian cancer: how can we make it better. J Clin Oncol 1994; 12:1743-1744. (Pubitemid 24349371)
9. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14:1552-1557. (Pubitemid 26134213)
10. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993. (Pubitemid 27106281)
11. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multi-drug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88:17-21. (Pubitemid 36062660)
12. Teneriello MG, Tseng PC, Crazier M, Hancock Messing MJ, Boehm KA, et al. Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2007; 25: 5525.
13. Rizvi NA, Riely GJ, Azzoli CG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Onc 2008; 26:639-643. (Pubitemid 351264360)